Advertisement

Tumor Biology

, Volume 37, Issue 9, pp 12877–12887 | Cite as

Construction of random tumor transcriptome expression library for creating and selecting novel tumor antigens

Original Article

Abstract

Novel tumor antigens are necessary for the development of efficient tumor vaccines for overcoming the immunotolerance and immunosuppression induced by tumors. Here, we developed a novel strategy to create tumor antigens by construction of random tumor transcriptome expression library (RTTEL). The complementary DNA (cDNA) from S180 sarcoma was used as template for arbitrarily amplifying gene fragments with random primers by PCR, then ligated to the C-terminal of HSP65 in a plasmid pET28a-HSP for constructing RTTEL in Escherichia coli. A novel antigen of A5 was selected from RTTEL with the strongest immunotherapeutic effects on S180 sarcoma. Adoptive immunotherapy with anti-A5 sera also inhibited tumor growth, further confirming the key antitumor roles of A5-specific antibodies in mice. A5 contains a sequence similar to protein-L-isoaspartate (D-aspartate) O-methyltransferase (PCMT1). The antisera of A5 were verified to cross-react with PCMT1 by Western blotting assay and vice versa. Both anti-A5 sera and anti-PCMT1 sera could induce antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity toward S180 cells by in vitro assay. Further assay with fluorescent staining showed that PCMT1 is detectable on the surface of S180 cells. Summary, the strategy to construct RTTEL is potential for creating and screening novel tumor antigens to develop efficient tumor vaccines. By RTTEL, we successfully created a protein antigen of A5 with significant immunotherapeutic effects on S180 sarcoma by induction of antibodies targeting for PCMT1.

Keywords

Random tumor transcriptome expression library S180 sarcoma Tumor antigen Protein-L-isoaspartate (D-aspartate) O-methyltransferase Humoral immunity. 

Notes

Acknowledgments

The authors are thankful for the project SRF150 supported by National Natural Science Foundation of China.

Supplementary material

13277_2016_5201_MOESM1_ESM.doc (1.7 mb)
ESM 1 (DOC 1725 kb)

References

  1. 1.
    Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol. 2011;18(1):23–34.CrossRefPubMedGoogle Scholar
  2. 2.
    Kiyamova R, Kostianets O, Malyuchik S, Filonenko V, Usenko V, Gurtovyy V, Khozayenko Y, Antonuk S, Old L, Gout I. Identification of tumor-associated antigens from medullary breast carcinoma by a modified SEREX approach. Mol Biotechnol. 2010;46:105–12.CrossRefPubMedGoogle Scholar
  3. 3.
    Kempa TJ, Hildesheimb A, Safaeianb M, Daunera JG, Pana Y, Porrasc C, Schillerd JT, Lowyd DR, Herreroc R, Pinto LA. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine. 2011;29(11):2011–4.Google Scholar
  4. 4.
    Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob J, Becker JC, Spatz A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, Keilholz U. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer melanoma Group in Metastatic Melanoma. J Clin Oncol. 2013;31(19):2413–20.CrossRefPubMedGoogle Scholar
  5. 5.
    Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, Lopez-Brea M, Vanakesa T, Jassem J, Kalofonos H, Perdeus J, Bonnet R, Basko J, Janilionis R, Passlick B, Treasure T, Gillet M, Lehmann FF, Brichard VG. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol. 2013;31(19):2396–403.CrossRefPubMedGoogle Scholar
  6. 6.
    Rosenberg SA. The curative potential of human cancer immunotherapy. Sci Transl Med. 2012;4:1–7.CrossRefGoogle Scholar
  7. 7.
    Thomas AA, Fisher JL, Ernstoff MS, Fadul CE. Vaccine-based immunotherapy for glioblastoma. CNS Oncol. 2013;2(4):331–49.CrossRefPubMedGoogle Scholar
  8. 8.
    Parmiani G, De Filippo A, Novellino L, Castelli C. Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol. 2007;178:1975–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Kim KM, Song MH, Kim MJ, Daudi S, Miliotto A, Old L, Odunsi K, Lee SY. A novel cancer/testis antigen KP-OVA-52 identifid by SEREX in human ovarian cancer is regulated by DNA methylation. Int J Oncol. 2012;41:1139–47.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Song MH, Choi KU, Shin DH, Lee CH, Lee SY. Identification of the cancer/testis antigens AKAP3 and CTp11 by SEREX in hepatocellular carcinoma. Oncol Rep. 2012;28:1792–8.PubMedGoogle Scholar
  11. 11.
    Yang HS, Zhang DM, Deng HX, Peng F, Wei YQ. Antitumor and anti-angiogenesis immunity induced by CR-SEREX-identified Xenopus RHAMM. Cancer Sci. 2010;101:862–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Cooper CD, Lawrie CH, Liggins AP, Collins GP, Hatton CS, Pulford K, Banham AH. Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens. PLoS One. 2011;6(8):e23916.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Song MH, Ha JC, Lee SM, Park YM, Lee SY. Identification of BCP-20 (FBXO39) as a cancer/testis antigen from colon cancer patients by SEREX. Biochem Biophys Res Commun 2011. 2011;408:195–201.CrossRefGoogle Scholar
  14. 14.
    Clark LC, Combs Jr GF, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher Jr JL, Park HK, Sanders Jr BB, Smith CL, Taylor JR. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. Nutritional prevention of cancer study group. JAMA. 1996;276(24):1957–63.CrossRefPubMedGoogle Scholar
  15. 15.
    Nadiminty N, Gao AC. Mechanisms of selenium chemoprevention and therapy in prostate cancer. Mol Nutr Food Res. 2008;52(11):1247–60.CrossRefPubMedGoogle Scholar
  16. 16.
    Chapman M, Warren EHI, Wu CJ. Applications of next-generation sequencing to blood and marrow transplantation. Biol Blood Marrow Transplant. 2012;18:S151–60.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Garraway L, Lander ES. Lessons from the cancer genome. Cell. 2013;153(1):17–37.CrossRefPubMedGoogle Scholar
  18. 18.
    Li L, Goedegebuure P, Mardis ER, Ellis MJ, Zhang X, Herndon JM, Fleming TP, Carreno BM, Hansen TH, Gillanders WE. Cancer genome sequencing and its pmplications for personalized cancer vaccines. Cancers. 2011;3(4):4191–211.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Heubeck B, Wendler O, Bumm K, Schäfer R, Müller-Vogt U, Häusler M, Meese E, Iro H, Steinhart H. Tumor-associated antigenic pattern in squamous cell carcinomas of the head and neck-analysed by SEREX. Eur J Cancer. 2013;49:e1–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Rio DC, Ares Jr M, Hannon GJ, Nilsen TW. Purification of RNA using TRIzol (TRI reagent). Cold Spring Harb Protoc. 2010;6:pdb. prot5439.CrossRefGoogle Scholar
  21. 21.
    Mansour FH, Pestov DG. Separation of long RNA by agarose-formaldehyde gel electrophoresis. Anal Biochem. 2013;441(1):18–20.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Chandler DP, Schreckhis RW, Smith JL, Bolton Jr H. Electroelution to remove humic compounds from soil DNA and RNA extracts. J Microbiol Methods. 1997;28(1):11–9.CrossRefGoogle Scholar
  23. 23.
    Spandidos A, Wang X, Wang H, Seed B. PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification. Nucleic Acids Res. 2010;38(suppl 1):D792–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Mayr UB, Kudela P, Atrasheuskaya A, Bukin E, Ignatyev G, Lubitz W. Rectal single dose immunization of mice with Escherichia coli O157: H7 bacterial ghosts induces efficient humoral and cellular immune responses and protects against the lethal heterologous challenge. Microb Biotechnol. 2012;5(2):283–94.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Tumban E, Peabody J, Peabody DS, Chackerian B. A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants. Vaccine. 2013;31(41):4647–54.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Guojun W, Wei G, Kedong O, Yi H, Yanfei X, Qingmei C, Yankai Z, Jie W, Hao F, Taiming L, Jingjing L, Rongyue C. A novel vaccine targeting gastrin-releasing peptide: efficient inhibition of breast cancer growth in vivo. Endocr Relat Cancer. 2008;15:149–59.CrossRefPubMedGoogle Scholar
  27. 27.
    Jinshu X, Jingjing L, Duan P, Zheng Z, Ding M, Jie W, Rongyue C, Zhuoyi H, Roque RS. A synthetic gonadotropin-releasing hormone (GnRH) vaccine for control of fertility and hormone dependent diseases without any adjuvant. Vaccine. 2005;23:4834–43.CrossRefPubMedGoogle Scholar
  28. 28.
    Sun X, Liu Y, Di D, Wu G, Guo H. Chemometric analysis of metabolism disorders in blood plasma of S180 and H22 tumor-bearing mice by high performance liquid chromatography-diode array detection. J Chemom. 2011;25(8):430–40.Google Scholar
  29. 29.
    Mizukami S, Kajiwara C, Ishikawa H, Katayama I, Yui K, Udono H. Both CD4 and CD8+ T cell epitopes fused to heat shock cognate protein 70 (hsc70) can function to eradicate tumors. Cancer Sci. 2008;99:1008–15.CrossRefPubMedGoogle Scholar
  30. 30.
    Zhou X, Kong N, Wang J, Fan H, Zou H, Horwitz D, Brand D, Liu Z, Zheng SG. All-trans retinoic acid sustains the stability and function of natural regulatory T cells in an inflammatory milieu. J Immunol. 2010;185:2675–9.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Xie Y, Sun H, Li D. Platycodin D is a potent adjuvant of specific cellular and humoral immune responses against recombinant hepatitis B antigen. Vaccine. 2009;27:757–64.CrossRefPubMedGoogle Scholar
  32. 32.
    Aikemu A, Umar A, Yusup A, Upur H, Berké B, Bégaud B, Bégaud B, Moore N. Immunomodulatory and antitumour effects of abnormal savda munziq on S180 tumor-bearing mice. BMC Complement Altern Med. 2012;12(1):157.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Park SY, Kim YH, Kim EK, Ryu EY, Lee SJ. Heme oxygenase-1 signals are involved in preferential inhibition of pro-inflammatory cytokine release by surfactin in cells activated with Porphyromonas gingivalis lipopolysaccharide. Chem Biol Interact. 2010;188:437–45.CrossRefPubMedGoogle Scholar
  34. 34.
    Nowak AK, Lake RA, Robinson BW. Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv Drug Deliv Rev. 2006;58(8):975–90.CrossRefPubMedGoogle Scholar
  35. 35.
    Berinstein NL. Enhancing cancer vaccines with immunomodulators. Vaccine. 2007;25s:b72–88.CrossRefGoogle Scholar
  36. 36.
    Gulley JL, Drake CG. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res. 2011;17(12):3884–91.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Kaufman HL, Kim-Schulze S, Manson K, DeRaffele G, Mitcham J, Seo KS, Kim DW, Marshall J. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J Transl Med. 2007;5:60.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Sambri I, Capasso R, Pucci P, Perna AF, Ingrosso D. The microRNA 15a/16-1 cluster down-regulates protein repair isoaspartyl methyltransferase in hepatoma cells: implications for apoptosis regulation. J Biol Chem. 2011;286(51):43690–700.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Amer M, Elhefnawi M, El-Ahwany E, Awad AF, Gawad NA, Zada S, Tawab FM. Hsa-miR-195 targets PCMT1 in hepatocellular carcinoma that increases tumor life span. Tumour Biol. 2014;35(11):11301–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol. 2010;28:4390–9.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  1. 1.College of Life Science and TechnologyHuazhong Agricultural UniversityWuhanChina
  2. 2.College of Life ScienceHubei UniversityWuhanChina

Personalised recommendations